Rheumatology Practice Management
Subscribe to Rheumatology Practice Management

Stay up to date with rheumatology news & updates by subscribing to receive the free RPM print publications or e‑Newsletters.

RPM e-Newsletter
RPM print publication

Web Exclusives

With Access to Care, Black Men in the United States Have Same Prostate Cancer Outcomes as White Men
In the United States, black men are twice as likely to die from prostate cancer as white men, and they are often diagnosed at a younger age and at later stages of the disease. Read More ›

Updated NCCN Prostate Cancer Guideline Emphasizes Risk Stratification
The updated prostate cancer guideline issued by the National Comprehensive Cancer Network (NCCN) continues to support early detection efforts in well-informed, healthy men, but acknowledges that the optimal screening of high-risk patients is not completely known. Read More ›

Adding Abiraterone to ADT May Decrease Resource Utilization in Castration-Naïve Prostate Cancer
The addition of abiraterone acetate (Zytiga) to androgen-­deprivation therapy (ADT) did not increase medical resource utilization in patients with metastatic castration-naïve prostate cancer who participated in the multinational LATITUDE clinical trial. Read More ›

Apalutamide and Enzalutamide Each Delays Prostate Cancer Metastasis by Approximately  2 Years

According to the results of 2 separate clinical trials presented at the 2018 Genitourinary Cancers Symposium, apalutamide and enzalutamide reduced the risk for metastasis and prolonged metastasis-free survival in patients with nonmetastatic castrate-resistant prostate cancer.

Read More ›

Medications Used for the Treatment of Prostate Cancer and the Associated ICD-10 Codes

FDA Under the Trump Administration: Can Scott Gottlieb Improve the Drug Approval Process?

Scott Gottlieb was recently confirmed as FDA Commissioner. It is believed that he would be able to swiftly execute changes that could help to accelerate drug approvals and lower drug prices to meet Trump’s goals.

Read More ›

Abiraterone Is Game-Changer in the Frontline Treatment of Advanced Prostate Cancer
“We think this is one of the biggest survival gains ever reported in a trial of an adult solid tumor,” said Nicholas D. James, PhD, BSc, MBBS, FRCP, FRCR. Read More ›

Adding Antiandrogen Therapy to Radiation Improves Survival in Recurrent Prostate Cancer—A New Standard of Care?

“This study’s findings—that adding antiandrogen therapy to the radiation typically used against recurrence reduces the incidence of metastasis, death from prostate cancer and overall deaths—will change the standard of care for patients experiencing a postoperative recurrence,” Dr Shipley added.

Read More ›

Biosimilar to Etanercept FDA Approved for Inflammatory Diseases
The US Food and Drug Administration (FDA) has approved etanercept-szzs, a biosimilar to etanercept (Enbrel), for the treatment of multiple inflammatory diseases, according to an announcement by the organization. The biosimilar injection has been approved to treat patients with moderate-to-severe rheumatoid arthritis; moderate-to-severe polyarticular juvenile idiopathic arthritis; active psoriatic arthritis; active ankylosing spondylitis; and chronic, moderate-to-severe plaque psoriasis. Read More ›

The US Food and Drug Administration (FDA) announced the approval of Inflectra (infliximab-dyyb)—a biosimilar to Remicade (infliximab)—for patients with chronic severe plaque psoriasis, and active ankylosing spondylitis or psoriatic arthritis. The biosimilar is also indicated for adult patients with moderately to severely active ulcerative colitis who have inadequately responded to standard therapy; in combination with methotrexate for patients with moderately to severely active rheumatoid arthritis; and patients aged ≥6 years with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy. Inflectra is the second biosimilar approved by the FDA. Read More ›

Page 2 of 4